Duloxetine Capsule, Delayed Release
Product Images NDC 71205-445

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71205-445). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-445-60 (Duloxetine 30mg 100s)

Label for Duloxetine 30 mg delayed-release capsules, 60 count, by Proficient Rx LP. The label shows dosage strength, quantity, and mentions each capsule contains 33.7 mg duloxetine hydrochloride equivalent to 30 mg duloxetine. Manufacturer is Alkem Laboratories Ltd., India. The label includes NDC 71205-445-60 and storage instructions at 25°C.*

FDA Label Image

Duloxetine-fig3 (Duloxetine Fig3)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline comparing Duloxetine HCL at doses of 60 mg twice daily, 60 mg once daily, 20 mg once daily, and placebo. Multiple lines represent each treatment group, showing trends in patient improvement across pain reduction percentages.*

FDA Label Image

Duloxetine-fig4 (Duloxetine Fig4)

A line graph comparing percentage improvement in pain from baseline to percentage of patients improved for Duloxetine HCl 60 mg twice daily, Duloxetine HCl 60 mg once daily, and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis represents the percentage of patients improved, showing greater improvement for Duloxetine doses compared to placebo.*

FDA Label Image

Duloxetine-fig7 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved in pain between placebo and Duloxetine 60/120 mg once daily, showing percent improvement in pain from baseline (BOCF) on the x-axis and percentage of patients improved on the y-axis.*

FDA Label Image

Duloxetine-fig8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for placebo and duloxetine 60 mg once daily. The graph shows two data series, highlighting trends over a range of percent improvements.*

FDA Label Image

Duloxetine-fig9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline using BOCF. Two lines represent placebo and Duloxetine 60/120 mg once daily, showing higher patient improvement percentages for Duloxetine across the improvement range.*

FDA Label Image

Duloxetine-figure1 (Duloxetine Figure1)

A line graph showing the proportion of patients with relapse over time (days) from randomization, comparing placebo and duloxetine treatments. The x-axis represents time in days up to 250, and the y-axis represents the proportion of patients with relapse, ranging from 0.0 to 1.0. The graph shows two lines: one for placebo and one for duloxetine, indicating relapse rates over approximately 200 days.*

FDA Label Image

Duloxetine-figure2 (Duloxetine Figure2)

A line graph showing the proportion of patients with relapse over time (days) from randomization to relapse. The x-axis represents time in days up to about 275, and the y-axis shows the proportion of patients with relapse ranging from 0 to 1. Three treatment groups are represented: Placebo, Duloxetine, and a third treatment (label not clearly visible). The graph tracks relapse progression among these groups over time.*

FDA Label Image

Duloxetine-structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride, depicting the molecular arrangement of the active ingredient duloxetine in its hydrochloride salt form as commonly represented in pharmaceutical product labeling.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.